Search

Search results

12 results found

Patient experience with endoscopic ultrasound and magnetic resonance cholangiopancreatography for pancreatic cancer screening (The PATRIOT study).

Merino, Andy Silva-Santisteban, Kevin Enrique Ariza Manzano, Sarah Ballou, Abraham Fourie Bezuidenhout, Katharine A Germansky, and Mandeep S Sawhney. 2026. “Patient Experience With Endoscopic Ultrasound and Magnetic Resonance Cholangiopancreatography for Pancreatic Cancer Screening (The PATRIOT Study).”. Pancreatology : Official Journal of the International Association of Pancreatology (IAP) . [et Al.] 26 (2): 259-64.

Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.

Deyhim, Tina, Alessandra Saraga, Ajay Gade, Grace Geeganage, Mostafa A Soliman, Samantha Zullow, Loren G Rabinowitz, et al. 2026. “Lower Drug Clearance of Adalimumab Is Associated With Proactive Therapeutic Drug Monitoring and Mucosal Healing in Patients With Inflammatory Bowel Disease.”. European Journal of Gastroenterology & Hepatology.

Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with Adalimumab.

Gade, Ajay, Alessandra Saraga, Tina Deyhim, Grace Geeganage, Samantha Zullow, Loren G Rabinowitz, Laurie B Grossberg, Adam S Cheifetz, and Konstantinos Papamichael. 2025. “Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated With Less Treatment Failure in Patients With Inflammatory Bowel Disease Treated With Adalimumab.”. Digestive Diseases and Sciences.

Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.

Gade, Ajay, Alessandra Saraga, Alfonso Elosua, Antony Ishan, Tina Deyhim, Nathan David Vanshelboym Rothschild, Adam S Cheifetz, and Konstantinos Papamichael. 2026. “Therapeutic Drug Monitoring for De-Escalating Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease.”. Expert Review of Clinical Pharmacology 19 (2): 167-74.

Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel Disease.

Saraga, Alessandra, Tina Deyhim, Ajay Gade, Grace Geeganage, Mostafa Soliman, Nathan David Vanshelboym Rothschild, Samantha Zullow, et al. 2026. “Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated With Treatment Failure in Patients With Inflammatory Bowel Disease.”. Journal of Clinical Medicine 15 (2).